C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma
Top Cited Papers
Open Access
- 19 February 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 506 (7489), 451-455
- https://doi.org/10.1038/nature13109
Abstract
Members of the nuclear factor-κB (NF-κB) family of transcriptional regulators are central mediators of the cellular inflammatory response. Although constitutive NF-κB signalling is present in most human tumours, mutations in pathway members are rare, complicating efforts to understand and block aberrant NF-κB activity in cancer. Here we show that more than two-thirds of supratentorial ependymomas contain oncogenic fusions between RELA, the principal effector of canonical NF-κB signalling, and an uncharacterized gene, C11orf95. In each case, C11orf95–RELA fusions resulted from chromothripsis involving chromosome 11q13.1. C11orf95–RELA fusion proteins translocated spontaneously to the nucleus to activate NF-κB target genes, and rapidly transformed neural stem cells—the cell of origin of ependymoma—to form these tumours in mice. Our data identify a highly recurrent genetic alteration of RELA in human cancer, and the C11orf95–RELA fusion protein as a potential therapeutic target in supratentorial ependymoma. At least two-thirds of supratentorial ependymomas contain oncogenic fusions between RELA, the principal effector of nuclear factor-κB (NF-κB) signalling, and uncharacterized gene C11orf95; C11orf95–RELA fusion proteins translocate spontaneously to the nucleus to activate NF-κB target genes, and rapidly transform neural stem cells to form tumours in mice In this issue of Nature two groups present independent genomic analyses on ependymomas, a type of tumour that occurs throughout the nervous system, but most commonly in the hindbrain in children. Mack et al. found a low overall mutation rate and no significant recurrent mutations in 47 hindbrain ependymomas. But posterior fossa group B tumours, a subgroup found predominantly in infants and associated with poor prognosis, were distinguished by a CpG island methylator phenotype. This subgroup is shown to be susceptible to various compounds that target epigenetic modifications, including an EZH2 inhibitor that showed efficacy in a mouse xenograft model. Parker et al. found the C11orf95–RELA fusion gene in about 70% of supratentorial tumours, but not in other ependymoma subgroups. The gene fusions arise through chromothripsis and lead to the expression of a fusion protein that constitutively activates NF-κB signalling. In a mouse model, expression of C11orf95–RELA in neural stem cells leads to the formation of brain tumours. These findings identify NF-κB signalling as a possible therapeutic target in patients with this type of ependymoma.Keywords
This publication has 28 references indexed in Scilit:
- An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for EpendymomaCancer Cell, 2011
- Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa EpendymomaCancer Cell, 2011
- CREST maps somatic structural variation in cancer genomes with base-pair resolutionNature Methods, 2011
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer DevelopmentCell, 2011
- Cross-species genomics matches driver mutations and cell compartments to model ependymomaNature, 2010
- Candidate Genes on Chromosome 9q33-34 Involved in the Progression of Childhood EpendymomasJournal of Clinical Oncology, 2009
- Conformal radiotherapy after surgery for paediatric ependymoma: a prospective studyThe Lancet Oncology, 2009
- Identification of Tumor-Specific Molecular Signatures in Intracranial Ependymoma and Association With Clinical CharacteristicsJournal of Clinical Oncology, 2006
- Radial glia cells are candidate stem cells of ependymomaCancer Cell, 2005
- The WHO Classification of Tumors of the Nervous SystemJournal of Neuropathology and Experimental Neurology, 2002